Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale ...

Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

Illumina, Inc. (NASDAQ:ILMN – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Wednesday after Morgan Stanley lowered their price target on the stock from $150.00 to ...

Illumina (NASDAQ:ILMN – Get Free Report) was downgraded by investment analysts at Barclays from an “equal weight” rating to ...

Illumina is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53 The company ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, expectations were $0.92. Operator: Good day, ladies and gentlemen, and ...

Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024 ...

Seahorse, Single Cell ENergetIc metabolism by profilIng Translation inHibition and transmission ... Sequencing libraries were generated using the NEBNext Ultra RNALibrary Prep Kit for Illumina (New ...

Illumina Inc (NASDAQ:ILMN). reported stronger-than-expected earnings for the fourth quarter of 2024, with both earnings per share (EPS) and revenue surpassing analysts' forecasts. Despite the positive ...